摘要
目的:通过对慢性阻塞性肺疾病(COPD)患者血清超敏C-反应蛋白(hs-CRP)、D-二聚体、N端前脑钠肽(NT-proBNP)进行检测,探讨其在COPD中的临床意义与应用价值。方法:选取100例COPD患者进行血清hs-CRP、D-二聚体、NT-proBNP检测,选取同期健康体检者50例进行血清hs-CRP、D-二聚体、NT-proBNP检测,将结果进行比较。结果:COPD急性期组和COPD缓解期组的血清hs-CRP、D-二聚体、NT-proBNP水平显著高于对照组,且COPD急性期组血清hs-CRP、D-二聚体、NT-proBNP显著高于COPD缓解期组,差异具有统计学意义(P<0.05);中度和重度COPD患者组血清hs-CRP、D-二聚体、NT-proBNP水平显著高于对照组,且重度COPD患者组血清hs-CRP、D-二聚体、NT-proBNP显著高于中度COPD患者组,差异具有统计学意义(P<0.05)。多因素Logistic回归分析显示,血清hs-CRP、D-二聚体、NT-proBNP水平是动脉粥样硬化疾病的独立危险因素。结论:血清hs-CRP、D-二聚体、NT-proBNP水平与COPD的发生、发展关系密切,联合检测hs-CRP、D-二聚体、NT-proBNP能够为COPD患者预测病情、了解疗效及监测预后提供重要临床依据。
Objective To explore the clinical significance and application value of serum high-sensitivity C-reactive protein(hs-CRP), D-dimer and N-terminal pro-brain natriuretic peptide(NT-proBNP) in patients with chronic obstructive pulmonary disease.Method Serum hs-CRP, D-dimer and NT-proBNP were detected in 100 patients with COPD and 50 health examination in the same period and the results were compared.Results The serum levels of hs-CRP, D-dimer and NT-proBNP in COPD acute phase group were significantly higher than those in and COPD remission phase group and control group and the differences were statistically significant(P<0.05). Those in COPD remission phase group were significantly higher than those in control group and the differences were statistically significant(P<0.05). Those in severe COPD patients group were significantly higher than those in moderate COPD patients group and control group and the differences were statistically significant(P<0.05). Those in moderate COPD patients group were significantly higher than those in control group and the differences were statistically significant(P<0.05). Multivariate logistic regression analysis showed that serum hs-CRP, D-dimer and NT-proBNP levels were independent risk factors of atherosclerosis.Conclusion Serum hs-CRP, D-dimer and NT-proBNP are closely related to the occurrence and development of COPD. Combined detection of hs-CRP, D-dimer and NT-proBNP can provide important clinical basis for predicting the condition, efficacy and prognosis of COPD patients.
作者
彭红云
陈德兴
PENG Hong-yun;CHEN De-xing(Department of Laboratory,maternal and child health hospitalof Xiashan District,Zhanjiang City,Zhanjiang 524011,China;Department of Internal Medicine,The People's Hospital of Chikan District,Zhanjiang City,Zhanjiang 524033,China)
出处
《吉林医学》
CAS
2022年第10期2780-2782,共3页
Jilin Medical Journal
